Is MUC1 a viable therapeutic target for patients with the asbestos-induced tumour malignant mesothelioma?
Is MUC1 a viable therapeutic target for patients with the asbestos-induced tumour malignant mesothelioma?
批准号:
nhmrc : 634377
负责人:
Dr Amanda Segal
金额:
$31.01万
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2010
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2010-01-01 至 2013-12-31
中文摘要
致命的石棉引起的癌症间皮瘤每年继续造成数万人死亡。大多数患者被诊断为晚期疾病。我们正在研究使用一种称为MUC1的特异性标志物来提高间皮瘤的诊断。改善诊断将减少开始治疗所需的时间。它还将减少医院的费用和病人必须接受的外科手术的数量。
英文摘要
The deadly asbestos-induced cancer mesothelioma is continuing to kill tens of thousands of people each year. Most patients are diagnosed with advanced disease. We are investigating the use of a specific marker, called MUC1, to improve mesothelioma diagnosis. Improved diagnosis will reduce the time taken to commence treatment. It will also reduce hospital costs and the number of surgical procedures a patients must undergo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
再生水系统中VBNC(Viable but nonculturable)病原菌复活机制与控制方法研究
-
批准号:51178242
-
项目类别:面上项目
-
资助金额:61.0万元
-
批准年份:2011
-
负责人:李丹
-
依托单位: